Name | 3-Fluoro-4-hydroxybenzaldehyde |
Synonyms | uoro-4-hydroxybenzaL 2-Fluoro-4-formylphenol 4-HYDROXY-3-FLUOROBENZALDEHYDE 3-FLUORO-4-HYDROXYBENZALDEHYDE 3-Fluoro-4-hydroxybenzaldehyde 3-Fluoro-4-hydroxy benzaldehyde Benzaldehyde, 3-fluoro-4-hydroxy- |
CAS | 405-05-0 |
EINECS | 609-839-2 |
InChIKey | QSBHJTCAPWOIIE-UHFFFAOYSA-N |
Molecular Formula | C7H5FO2 |
Molar Mass | 140.11 |
Density | 1.4710 (estimate) |
Melting Point | 121-124°C |
Boling Point | 225.6±20.0 °C(Predicted) |
Appearance | powder to crystal |
Color | Light yellow to Yellow to Orange |
BRN | 3234259 |
pKa | 6.52±0.18(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
Sensitive | Air Sensitive |
MDL | MFCD00016626 |
Hazard Symbols | Xi - Irritant |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R52 - Harmful to aquatic organisms R41 - Risk of serious damage to eyes R37/38 - Irritating to respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S27 - Take off immediately all contaminated clothing. S39 - Wear eye / face protection. |
HS Code | 29145090 |
Hazard Class | IRRITANT |
Use | 3-fluoro-4-hydroxybenzaldehyde can be used to synthesize 3-cyclopropylmethoxy-4-difluoromethoxybenzoic acid, which is the preparation of roflumilast Impurities and intermediates. |
Application | 3-fluoro-4-hydroxybenzaldehyde can be used to prepare roflumilast key intermediate 3-cyclopropylmethoxy-4-difluoromethoxybenzoic acid. Roflumilast (Roflumilast) was developed by the Swiss Nycomed Company and the American Forest Company. It is the first and currently the only selective phosphodiesterase-4 inhibitor that can be used orally for the treatment of chronic obstructive pulmonary disease (COPD). In May 2010, the European Medicines Agency (EMEA) approved it for severe chronic obstructive pulmonary disease and chronic bronchitis. In February 2011, the US Food and Drug Administration (FDA) approved it for the treatment of severe COPD. The drug has novel mechanism of action, definite curative effect, wide application population and broad market prospect. |
Preparation | 3-fluoro-4-methoxybenzaldehyde 14(5.00g,32.5mmol) was mixed with 48% HBr(30mL), heated to 140°C and stirred in an argon atmosphere for 3 hours. The mixture was diluted with water (150mL) and extracted with dichloromethane (2 × 100mL). The combined organic layers were washed with a saline solution and dried with sodium sulfate. The solvent was removed by vacuum to obtain the compound 3-fluoro-4-hydroxybenzaldehyde (4.36g,30.2mmol, 97% yield) as a brown solid. |